Appointment of Corporate Broker

RNS Number : 2533H

Destiny Pharma PLC

23 November 2022

 

23 November 2022

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Appointment of Corporate Broker

Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, is pleased to announce the appointment of Shore Capital as joint corporate broker, to work alongside the Company's Nominated Adviser and existing corporate broker finnCap Ltd, with immediate effect.

For further information, please contact:

Destiny Pharma plc  Neil Clark, CEO Shaun Claydon, CFO	[phone] [e-mail]
finnCap Ltd (Nominated Adviser and Joint Broker)  Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance Alice Lane / Nigel Birks / Harriet Ward, ECM	[phone]
Shore Capital (Joint Broker)  Daniel Bush / James Thomas / Lucy Bowden	[phone]
Optimum Strategic Communications Mary Clark / Nick Bastin / Manel Mateus	[phone] [e-mail]
MC Services AG Anne Hennecke / Andreas Burckhardt	[phone]
Stern IR - US Janhavi Mohite	[phone] [e-mail]

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

For further information on the company, please visit   https://www.destinypharma.com

 

END

 

 

APPEALFAAFLAFFA